V
Visiopharm
Health Tech & Medtech · Hørsholm, Denmark · Founded 2001
AI-driven precision pathology and tissue image analysis software MoreLess
In 2001, Johan Dore and Michael Grunkin founded Visiopharm in Denmark, setting out to revolutionize the field of digital pathology. Their vision was to harness the power of AI to enhance image analysis and workflow standardization in pathology labs. This innovation aimed to improve diagnostic accuracy and efficiency, addressing a critical need in medical diagnostics.
Visiopharm's journey was marked by strategic growth and innovation. In 2016, the company expanded its capabilities by acquiring LRI Instrument AB, a move that strengthened its technological foundation and broadened its market reach. This acquisition was a pivotal moment, enabling Visiopharm to offer more comprehensive solutions to its clients.
Over the years, Visiopharm secured significant funding to fuel its growth. By 2025, the company had raised a total of $26.3 million over several funding rounds, attracting investments from notable entities like ATP and BankInvest. This financial backing was crucial in supporting Visiopharm's research and development efforts, allowing it to stay at the forefront of digital pathology innovation.
Today, Visiopharm stands as a leader in the field, known for its cutting-edge AI-driven solutions that empower pathologists worldwide. The company's commitment to advancing medical diagnostics continues to drive its success, making it a key player in the healthcare technology landscape.
Company overview
Visiopharm company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2001
- Headquarters
- Hørsholm, Denmark
- Employees
- 91
- Open positions
- None listed
- Dealroom signal
- 64.8
- Investment activity
- 1 companies · latest Dec 2016
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Visiopharm funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | May 2026 | $0 | — | Grundium | ↗ |
| LATE VC✓Equity / VC | Sep 2020 | $0 | — | BankInvest · C.L. Davids Fond og Samling · ATP · Northcap | — |
| GRANT✓Other financing | Dec 2019 | $330K | — | UK Research and Innovation | — |
| LATE VC✓Equity / VC | Aug 2019 | $15M | $59M | Northcap · Vator · ATP | — |
| EARLY VC✓Equity / VC | Aug 2018 | $14M | $56M | Northcap · ATP | — |
| GROWTH EQUITY VCEquity / VC | Oct 2007 | Northcap | — | ||
| SPINOUT✓Other financing | Jul 2001 | Technical University of Denmark | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | Profit | Margin |
|---|---|---|---|---|
| 2026 | $19M | 0% | −$2.5M | -13.3% |
| 2025 | $19M | +10.5% | −$2.5M | -13.3% |
| 2024 | $17M | +5.4% | −$2.5M | -14.7% |
| 2023 | $16M | -17.6% | ||
| 2022 | $20M | +25.3% | ||
| 2021 | $16M | +28.8% | ||
| 2020 | $12M | — |
Growth signals
Visiopharm website traffic
Latest recorded traffic for Visiopharm is 8.1K monthly website visits, up 20.9% over the last three months. Visiopharm's team declined 9% over the past year.
Comparisons
Visiopharm compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Visiopharm investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Visiopharm's talent
Source: Dealroom Talent Intelligence.
Investors
10 investors on Visiopharm's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Visiopharm has talent and traffic
team presence
In the news
Latest news about Visiopharm
Recent press, funding announcements, and product moves mentioning Visiopharm — open to read from the original sources.
Market sentiment
What the market is saying about Visiopharm
An AI-synthesized read of the highest-engagement posts about Visiopharm on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Visiopharm’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.